BioSpace News Archive

Policy

Esperion Announces U.S. FDA Acceptance of New Drug Applications (NDAs) for Both Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet for Filing and Regulatory Review

Bempedoic Acid is an Oral, Once-daily ATP Citrate Lyase (ACL) Inhibitor that Reduces Cholesterol and Fatty Acid Synthesis in the Liver

May 6, 2019
·
8 min read
Deals

Banco Sabadell Gives ADL Bionatur Solutions An Upside Potential Of 78%

Sales estimated to double in 2019 and exceed EUR 50 million

May 6, 2019
·
2 min read
Biotech Bay

TLC Highlights Data Presentations on Lead Product Candidate TLC599 at Osteoarthritis Research Society International (OARSI) 2019 World Congress

TLC presented data from numerous recent studies on its lead product candidate, TLC599, at the Osteoarthritis Research Society International World Congress, which took place May 2 to 5, 2019 in Toronto, Canada.

May 6, 2019
·
4 min read
Drug Development

Neurocrine’s Opicapone Plus Levodopa Improves Parkinson’s Symptoms

San Diego-based Neurocrine Biosciences presented data from two Phase III clinical trials of opicapone, a once-daily, oral catechol-O-methyltransferase (COMT) inhibitor for Parkinson’s disease.

May 6, 2019
·
3 min read
·
Mark Terry
Deals

Lundbeck Acquires Abide Therapeutics for $250M, Gains San Diego Discovery Site

With a $250 million cash down payment, Denmark’s H. Lundbeck A/S snapped up San Diego-based Abide Therapeutics to gain a novel discovery platform and a U.S.-based research hub.

May 6, 2019
·
2 min read
·
Alex Keown
FDA

Genentech’s Kadcyla Wins Second FDA Approval for HER2-Positive Breast Cancer

The FDA rapidly reviewed and approved the medication under the FDA’s Real-Time Oncology Review (RTOR) and Assessment Aid pilot program.

May 6, 2019
·
2 min read
·
Alex Keown
Publications of Secarna Pharmaceuticals’ immuno-oncology data in peer-reviewed scientific journals support potential of LNAplusTM antisense oligonucleotide platform for discovering novel cancer therapies

New strategies urgently needed to prevent tumors from evading the immune system and to make them more susceptible to attack by immune cells

May 6, 2019
·
6 min read
Drug Development

Cytokinetics’ ALS Treatment Fails to Hit Endpoints in Phase II, Company Notes Several Positive Results

Despite not hitting endpoints, Cytokinetics noted that the FORTITUDE-ALS trial demonstrated consistency of effect for doses, endpoints and timepoints.

May 6, 2019
·
3 min read
·
Alex Keown
Bio NC

Your Feedback Matters! The Right Opportunity

As a valued member of our BioSpace community, we are eager to hear more from you and other readers in 2019. We want to know your ‘right opportunity’ to consider a new job.

May 6, 2019
·
1 min read
·
Editorial Staff
Business

Artificial Intelligence is Ramping up in Drug Development

AstraZeneca announced a long-term collaboration deal with BenevolentAI, a UK-based company focused on combining computational medicine and advanced artificial intelligence.This deal only marks one of the most recent AI team-ups announced in the biopharma industry.

May 6, 2019
·
5 min read
·
Mark Terry